Monoferric is owned by Pharmacosmos As.
Monoferric contains Ferric Derisomaltose.
Monoferric has a total of 2 drug patents out of which 0 drug patents have expired.
Monoferric was authorised for market use on 16 January, 2020.
Monoferric is available in solution;intravenous dosage forms.
Monoferric can be used as method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose.
The generics of Monoferric are possible to be released after 14 August, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US10414831||PHARMACOSMOS AS||Stable iron oligosaccharide compound|| |
(5 years from now)
|US8815301||PHARMACOSMOS AS||Stable iron oligosaccharide compound|| |
(6 years from now)
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic